Chaperone Technologies, Inc.
City: East Stroudsburg
Website: www.chaperonetechnologies.com
Chaperone Technologies develops novel products based on DnaK Inhibition to target difficult-to-treat and drug-resistant bacterial pathogens across a broad range of infectious diseases. This investment will allow Chaperone to develop and expand the company’s proprietary antimicrobial technology, including the development of its DnaK Inhibitors in synergy with other antimicrobials. Current applications include complicated urinary tract infections, respiratory infections, and Category A biowarfare pathogens.